• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study.

作者信息

Steinhubl S R

机构信息

Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, Lackland, TX, USA.

出版信息

J Thromb Thrombolysis. 2000 Apr;9(3):199-205. doi: 10.1023/a:1018754309025.

DOI:10.1023/a:1018754309025
PMID:10728017
Abstract
摘要

相似文献

1
Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study.评估接受冠状动脉介入治疗患者使用糖蛋白IIb/IIIa抑制剂时的最佳血小板抑制水平。GOLD研究的原理与设计。
J Thromb Thrombolysis. 2000 Apr;9(3):199-205. doi: 10.1023/a:1018754309025.
2
Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens?初始血小板活性可能预测慢性口服糖蛋白IIb/IIIa受体阻滞剂后的疗效：我们是否仍应考虑统一的治疗方案？
Thromb Res. 2000 Jul 1;99(1):105-7. doi: 10.1016/s0049-3848(00)00229-2.
3
Monitoring platelet GP IIb/IIIa antagonist therapy.监测血小板糖蛋白IIb/IIIa拮抗剂治疗。
Circulation. 1998;97(1):5-9. doi: 10.1161/01.cir.97.1.5.
4
The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.使用即时检测的海伦娜ICHO/血小板功能分析仪和Accumetrics Ultegra RPFA通过糖蛋白IIb-IIIa拮抗剂评估血小板功能。
J Thromb Thrombolysis. 2004 Dec;18(3):163-9. doi: 10.1007/s11239-005-0341-x.
5
Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.
Catheter Cardiovasc Interv. 2001 Jul;53(3):346-51. doi: 10.1002/ccd.1179.
6
Platelet glycoprotein IIb/IIIa inhibitors.血小板糖蛋白IIb/IIIa抑制剂
Circulation. 2003 Feb 11;107(5):E39-9. doi: 10.1161/01.cir.0000053955.01455.5a.
7
Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.依替巴肽静脉注射在接受经皮冠状动脉介入治疗患者中的治疗应用：急性冠状动脉综合征和择期支架置入术。
Am J Cardiovasc Drugs. 2004;4(1):31-41. doi: 10.2165/00129784-200404010-00004.
8
A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.血小板糖蛋白IIb/IIIa抑制剂治疗对经皮冠状动脉介入术后院内结局影响的倾向性分析
Am J Cardiol. 2004 Feb 15;93(4):524-5. doi: 10.1016/j.amjcard.2003.07.051.
9
Optimizing antiplatelet therapy in coronary interventions.优化冠状动脉介入治疗中的抗血小板治疗
Clin Cardiol. 2000 Nov;23 Suppl 6(Suppl 6):VI-8-13. doi: 10.1002/clc.4960231104.
10
Applications of anti-platelet monitoring in catheterization laboratory.抗血小板监测在导管室的应用。
J Thromb Thrombolysis. 2000 Apr;9(3):293-301. doi: 10.1023/a:1018724827741.

引用本文的文献

1
Glycoprotein receptor inhibitors in the management of acute coronary syndromes.糖蛋白受体抑制剂在急性冠状动脉综合征治疗中的应用
Curr Cardiol Rep. 2002 Jul;4(4):301-12. doi: 10.1007/s11886-002-0066-9.
2
Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.通过凝集测定法、流式细胞术、单血小板计数和快速血小板功能分析仪对糖蛋白IIb/IIIa抑制剂及其活性进行比较。
J Thromb Thrombolysis. 2001 Oct;12(2):129-39. doi: 10.1023/a:1012967320220.
3
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.

本文引用的文献

1
High-Dose Abciximab During Coronary Angioplasty in a Patient with Essential Thrombocytosis.原发性血小板增多症患者冠状动脉血管成形术期间使用大剂量阿昔单抗
J Invasive Cardiol. 1998 Apr;10(3):173-176.
2
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.
Circulation. 1999 Nov 9;100(19):1977-82. doi: 10.1161/01.cir.100.19.1977.
3
Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.阿昔单抗、替罗非班或依替巴肽对接受经皮冠状动脉介入治疗的不稳定型心绞痛患者血小板抑制的时间进程、程度及一致性。
健康受试者中阿昔单抗或替罗非班与普通肝素或低分子量肝素相互作用的药效学特征。
Br J Clin Pharmacol. 2001 Sep;52(3):297-305. doi: 10.1046/j.0306-5251.2001.01446.x.
4
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
J Thromb Thrombolysis. 2001 Apr;11(2):151-4. doi: 10.1023/a:1011228817265.
5
Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.糖蛋白IIb-IIIa抑制剂对血小板聚集的抑制作用
J Thromb Thrombolysis. 2001 Apr;11(2):99-110. doi: 10.1023/a:1011216414539.
6
Monitoring antiplatelet therapy: What is the best method?监测抗血小板治疗：最佳方法是什么？
Clin Pharmacokinet. 2000 Dec;39(6):445-58. doi: 10.2165/00003088-200039060-00005.
7
The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome.抗血小板治疗的未来：优化急性冠状动脉综合征患者的管理
Clin Cardiol. 2000 Nov;23 Suppl 6(Suppl 6):VI-23-8. doi: 10.1002/clc.4960231107.
8
Applications of anti-platelet monitoring in catheterization laboratory.抗血小板监测在导管室的应用。
J Thromb Thrombolysis. 2000 Apr;9(3):293-301. doi: 10.1023/a:1018724827741.
Am J Cardiol. 1999 Aug 15;84(4):391-5. doi: 10.1016/s0002-9149(99)00321-5.
4
Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA.在接受经皮冠状动脉腔内血管成形术（PTCA）的患者输注c7E3 Fab期间及之后，通过定量流式细胞术测定全血中游离和总血小板糖蛋白IIb/IIIa。
Thromb Haemost. 1999 Jun;81(6):869-73.
5
Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
J Thromb Thrombolysis. 1999 Jun;7(3):265-76. doi: 10.1023/a:1008931126871.
6
Rapid platelet-function assay: an automated and quantitative cartridge-based method.快速血小板功能检测：一种基于试剂盒的自动化定量方法。
Circulation. 1999 Feb 9;99(5):620-5. doi: 10.1161/01.cir.99.5.620.
7
Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.冠状动脉支架置入术后糖蛋白IIb-IIIa受体拮抗剂对血小板膜糖蛋白的影响。
Thromb Haemost. 1998 Dec;80(6):994-1001.
8
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
Circulation. 1998;98(25):2829-35. doi: 10.1161/01.cir.98.25.2829.
9
Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.诱导纤维蛋白原结合和血小板聚集作为各种糖蛋白IIb/IIIa（αIIbβ3）抑制剂的一种潜在固有特性。
Blood. 1998 Nov 1;92(9):3240-9.
10
Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.短期使用阿昔单抗治疗的药效学特征显示，血小板抑制作用持续时间延长，且从糖蛋白IIb/IIIa受体阻滞状态逐渐恢复。
Circulation. 1998 May 5;97(17):1680-8. doi: 10.1161/01.cir.97.17.1680.